Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines

BackgroundOne of the major reasons for poor prognosis of pancreatic cancer is its high resistance to currently available chemotherapeutic agents. In recent years, focal adhesion kinase (FAK), a central molecule in extracellular matrix (ECM)/integrin-mediated signaling, has been thought to be a key determinant of chemoresistance in cancer cells. In this study, we aimed to determine the roles of FAK phosphorylation in the intrinsic chemoresistance of pancreatic cancer cell lines.ResultsOur results showed that, the level of constitutive phosphorylation of FAK at Tyr397 correlated with the extent of intrinsic resistance to Gemcitabine (Gem) in four pancreatic cancer cell lines. Moreover, in Panc-1 cells, which had high expression of pFAK, specific inhibition of constitutive FAK phosphorylation by either RNAi or FRNK overexpression decreased the phosphorylation of Akt, reduced the levels of survivin expression and Bad phosphorylation at Ser136 and increased Gem-induced cytotoxicity and apoptosis. However, in AsPC-1 cells with a low level of pFAK, neither FAK RNAi nor FRNK overexpression affected Gem-induced cell apoptosis. We further found that laminin (LN) induced FAK and Akt phosphorylation in a time-dependent manner, increased the levels of survivin and pBad (pS136) and decreased Gem-induced cytotoxicity and apoptosis in AsPC-1 cells; Specific inhibition of LN-induced FAK phosphorylation by either FAK RNAi or FRNK overexpression suppressed the effects of LN on AsPC-1 cells. Moreover, inhibition of constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in AsPC-1 cells by a novel and more specific FAK phosphorylation inhibitor PF-573,228 showed similar results with those of FAK phosphorylation inhibition by FAK RNAi or FRNK overexpression.ConclusionsIn conclusion, our research demonstrates for the first time that both constitutive and LN-induced FAK phosphorylation contribute to increased intrinsic chemoresistance to Gem in pancreatic cancer cell lines and these effects are partly due to the regulation of Akt and Bad phosphorylation and survivin expression. Development of selective FAK phosphorylation inhibitors may be a promising way to enhance chemosensitivity in pancreatic cancer.

[1]  Kazuhiro Takahashi,et al.  Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel* , 2002, The Journal of Biological Chemistry.

[2]  A. Ko.  Future strategies for targeted therapies and tailored patient management in pancreatic cancer. , 2007, Seminars in oncology.

[3]  M. Weiser-Evans,et al.  Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. , 2003, Molecular biology of the cell.

[4]  V. Golubovskaya,et al.  Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines , 2005, Melanoma research.

[5]  H. Putter,et al.  Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  J. Iredale,et al.  Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma , 2004, Clinical Cancer Research.

[7]  X. Shi,et al.  Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo , 2009, Cancer Gene Therapy.

[8]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[9]  G. Abou-Alfa,et al.  Cytotoxic therapy for advanced pancreatic adenocarcinoma. , 2007, Seminars in oncology.

[10]  G. Kouraklis,et al.  Clinical significance of FAK expression in human neoplasia. , 2008, Histology and histopathology.

[11]  C. Rocha-Lima,et al.  New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. , 2008, The oncologist.

[12]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[13]  E. Jensen,et al.  Molecular targeted therapies for pancreatic cancer. , 2008, American journal of surgery.

[14]  R. Qin,et al.  siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine Chemosensitivity , 2008, Digestive Diseases and Sciences.

[15]  W. Zong,et al.  Chemotherapeutic approaches for targeting cell death pathways. , 2006, The oncologist.

[16]  R. Juliano,et al.  Clinging to life: cell to matrix adhesion and cell survival , 2005, Cancer and Metastasis Reviews.

[17]  T. Tsuruo,et al.  β1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms , 2008, Apoptosis.

[18]  F. Tsai,et al.  Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. , 2009, Lung cancer.

[19]  N. Lemoine,et al.  Targeted therapies for pancreatic cancer. , 2008, British medical bulletin.

[20]  N. Cordes.  Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. , 2006, Cancer letters.

[21]  T. Seufferlein,et al.  Palliative treatment of pancreatic cancer , 2008, Journal of digestive diseases.

[22]  R. Rintoul,et al.  ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase , 2006, Cell Death and Differentiation.

[23]  J. Hayakawa,et al.  Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. , 2000, Cancer research.

[24]  M. Löhr,et al.  Expression and Function of Receptors for Extracellular Matrix Proteins in Human Ductal Adenocarcinomas of the Pancreas , 1996, Pancreas.

[25]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[26]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[27]  J. Parsons,et al.  A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125FAK , 1996, Nature.

[28]  B. van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[29]  H. Friess,et al.  Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents , 2002, Cancer Chemotherapy and Pharmacology.

[30]  Chi-Tang Ho,et al.  Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down‐regulation of Src, ERK, and Akt survival signaling in human colon cancer cells , 2005, Journal of cellular biochemistry.

[31]  S. Ashley,et al.  RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. , 2003, Biochemical and biophysical research communications.

[32]  D. Ito,et al.  Clinical Significance of Focal Adhesion Kinase in Resectable Pancreatic Cancer , 2006, World Journal of Surgery.

[33]  H. Friess,et al.  Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes , 2002, Oncology.

[34]  B. van de Water,et al.  Focal Adhesion Kinase and Protein Kinase B Cooperate to Suppress Doxorubicin-Induced Apoptosis of Breast Tumor Cells , 2006, Molecular Pharmacology.

[35]  Christopher M. Williams,et al.  Characterization of a novel focal adhesion kinase inhibitor in human platelets , 2009, Biochemical and biophysical research communications.

[36]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[37]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[38]  W. Dalton,et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.

[39]  A. Magis,et al.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. , 2008, Journal of medicinal chemistry.

[40]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[41]  J. Parsons,et al.  Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention , 2008, Clinical Cancer Research.

[42]  T. Tsuruo,et al.  Fak/Src signaling in human intestinal epithelial cell survival and anoikis: Differentiation state‐specific uncoupling with the PI3‐K/Akt‐1 and MEK/Erk pathways , 2007, Journal of cellular physiology.

[43]  Z. Hua,et al.  Chapter 3 FAK Expression , 2008 .

[44]  Christopher Autry,et al.  Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor* , 2007, Journal of Biological Chemistry.

[45]  Bob van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[46]  K. Jauch,et al.  Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[47]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[48]  Z. Hua,et al.  FAK expression regulation and therapeutic potential. , 2008, Advances in cancer research.

[49]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Tsuchida,et al.  Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.